118802-40-7

Usage

Uses

Used in Pharmaceutical Industry:
7-Methylindole-3-acetonitrile is used as a key intermediate in the synthesis of anti-inflammatory and anti-cancer drugs. Its unique chemical structure allows for the development of pharmaceuticals that target specific biological pathways, offering potential therapeutic benefits in the treatment of various inflammatory and neoplastic conditions.
Used in Fine Chemicals Production:
In the fine chemicals sector, 7-Methylindole-3-acetonitrile is utilized as a precursor for the manufacturing of specialty chemicals. Its versatility in chemical reactions enables the production of a wide range of high-value compounds used in various industrial applications, such as agrochemicals, dyes, and fragrances.
Safety Considerations:
Due to its potential hazards if not handled properly, it is crucial to exercise caution when working with 7-Methylindole-3-acetonitrile. Appropriate safety measures, including the use of personal protective equipment and adherence to proper handling and storage protocols, should be implemented to minimize risks associated with its use.

Upstream product

• 10472-24-9 methyl 2-oxocyclopentane-1-carboxylate 
• 65818-01-1 2-methyl-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one 

Downstream Products

• 69390-17-6 2-methyl-6,7-dihydro-5H-cyclopentapyrimidin-4-ylamine 
• 36274-29-0 2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine 
• 1452392-86-7 N-(4-methoxyphenyl)-N,2-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride 
• 1452392-87-8 N-(4-ethoxyphenyl)-N,2-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride 
• 1452392-73-2 N,2-dimethyl-N-p-tolyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine 

Relevant academic research and scientific papers

Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer

Novel selective histone deacetylase 6 (HDAC6) inhibitors using the quinazoline as the cap were designed, synthesized, and evaluated for HDAC enzymatic assays. N-Hydroxy-4-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)butanamide, 23bb, was the

Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents

A series of 21 substituted cyclopenta[d]pyrimidines were synthesized as an extension of our discovery of the parent compound (±)-1·HCl as an anti-microtubule agent. The structure-activity relationship indicates that the N-methyl and a 4N-methoxy groups appear important for potent activity. In addition, the 6-substituent in the parent analogue is not necessary for activity. The most potent compound 30·HCl was a one to two digit nanomolar inhibitor of most tumor cell proliferations and was up to 7-fold more potent than the parent compound (±)-1·HCl. In addition, 30·HCl inhibited cancer cell proliferation regardless of Pgp or βIII-tubulin status, both of which are known to cause clinical resistance to several anti-tubulin agents. In vivo efficacy of 30·HCl was demonstrated against a triple negative breast cancer xenograft mouse model. Compound 30·HCl is water-soluble and easily synthesized and serves as a lead compound for further preclinical evaluation as an antitumor agent.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.